超声介入无水乙醇量化治疗复发性肝癌临床研究  

Clinical Study on Percutaneous Quantified Ethanol Injection in the Treatment of Recurrent Hepatocellular Carcinoma

作　　者：林学英[1] 林礼务[1] 薛恩生[1] 何以敉[1] 高上达[1] 林晓东[1] 吴丽足[1] 

机构地区：[1]福建省福建医科大学附属协和医院超声科,福建省超声医学研究所,福州市350001

出　　处：《中国超声医学杂志》2005年第9期650-653,共4页Chinese Journal of Ultrasound in Medicine

基　　金：福建省科委研究基金项目(No.2000Z138)

摘　　要：目的评价超声介入无水乙醇量化注射(PQEI)治疗复发性肝癌的临床应用价值.方法临床病理证实的复发性肝癌213例,行PQEI治疗,注射量按回归方程Y=2.885X(当肿瘤直径≤5 cm时),Y=1.805X(当肿瘤直径＞5 cm时)计算,X为肿瘤最大直径,单位为cm;Y为注射乙醇量,单位为ml.所有病例随访12～60个月.观察临床症状与体征,并结合相关检查结果.统计1～5年生存率.结果经PQEI治疗后肿瘤平均直径从3.5 cm降为2.7 cm,1～5年生存率分别为91.1%、81.7%、70.4%、61.9% 和 51.5%,中数生存期为46.8个月.结论超声介入无水乙醇量化治疗复发性肝癌有较高的临床应用价值,值得深入研究.Objective To evaluate the clinical applied value of percutaneous quantified ethanol injection （PQEI） in the treatment of recurrent hepatocellular carcinoma （HCC）. Methods The clinicopathologically proved HCC in 238 cases were taken PQEI. The quantity of ethanol was calculated according to the regressive equations which were Y = 2. 885X when the mass was≤5 cm in diameter and Y = 1. 805 X when the mass was 〉5 cm in diameter （X cm is the maximal diameter of the mass and Y ml is the ethanol quantity） . The follow-up period lasted 12-60 months. The therapeutic efficacy was assessed by clinical symptom, the result of US, CT, MRI. Color 3- Dimensional ultrasound （C-3DUS） and biopsy. The survival rates were calculated. Results All the 303 nodules of HCC in 213 cases shrank from 3.5 cm to 2.7 cm in average diameter after 2-8 weeks since the last PEI. The survival rates of 1, 2, 3, 4, 5 years were 91.1%, 81.7%, 70.4%, 61.9% and 51.5%, respectively. The median survival period was 46.8 months. Conclusions The treatment efficacy of PQEI on recurrent hepatocellular carcinoma is of high clinical application value and deserves further research.

关 键 词：超声介入 无水乙醇 药物量化治疗 复发性肝癌 临床应用 

分 类 号：R735.7[医药卫生—肿瘤] R730.41[医药卫生—临床医学]